Use of vascular endothelial growth factor to treat...

Details Use of vascular endothelial growth factor to treat... Use of vascular endothelial growth factor to treat...

2007-05-29

2007-05-29

Landsman, Robert S. (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S963000, C514S964000, C514S969000

Reexamination Certificate

active

09499468

ABSTRACT:
The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.

REFERENCES:
patent: 5073492 (1991-12-01), Chen et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5283354 (1994-02-01), Lemischka
patent: 5326695 (1994-07-01), Andersson et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5633147 (1997-05-01), Meissner et al.
patent: 5652225 (1997-07-01), Isner
patent: 5661133 (1997-08-01), Leiden et al.
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5861301 (1999-01-01), Terman et al.
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6121246 (2000-09-01), Isner
patent: 6130071 (2000-10-01), Alitalo et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6245530 (2001-06-01), Alitalo et al.
patent: 6297238 (2001-10-01), Doyle et al.
patent: 6361946 (2002-03-01), Alitalo et al.
patent: 6403088 (2002-06-01), Alitalo et al.
patent: 6451764 (2002-09-01), Lee et al.
patent: 6515105 (2003-02-01), Alitalo et al.
patent: 6645933 (2003-11-01), Alitalo et al.
patent: 6660744 (2003-12-01), Hirst et al.
patent: 6713474 (2004-03-01), Hirst et al.
patent: 2002/0019350 (2002-02-01), Levine et al.
patent: 2002/0086004 (2002-07-01), Adnot et al.
patent: 2002/0111362 (2002-08-01), Rubinfeld
patent: 2002/0156081 (2002-10-01), Hirst et al.
patent: 2003/0125523 (2003-07-01), Alitalo et al.
patent: 2003/0153752 (2003-08-01), Hirst et al.
patent: 2003/0187001 (2003-10-01), Calderwood et al.
patent: 2003/0211988 (2003-11-01), Epstein
patent: 2004/0002140 (2004-01-01), Gilbert et al.
patent: 2004/0248781 (2004-12-01), Kerbel
patent: 2005/0118180 (2005-06-01), Rubinfeld
patent: 2006/0014252 (2006-01-01), Lyman
patent: 710696 (1999-09-01), None
patent: 0 186 084 (1986-07-01), None
patent: 0 399 816 (1990-11-01), None
patent: 0-476983 (1992-03-01), None
patent: 0-476983 (1992-03-01), None
patent: 0476983 (1992-03-01), None
patent: 0-506477 (1992-09-01), None
patent: 0-506477 (1992-09-01), None
patent: 64-38100 (1989-02-01), None
patent: 2-117698 (1990-05-01), None
patent: WO 91/02058 (1991-02-01), None
patent: 92/14748 (1992-09-01), None
patent: WO 94/11506 (1994-05-01), None
patent: 95/19985 (1995-07-01), None
patent: 95/24414 (1995-09-01), None
patent: WO-95/24473 (1995-12-01), None
patent: 96/05856 (1996-02-01), None
patent: 96/39515 (1996-12-01), None
patent: WO-97/00271 (1997-01-01), None
patent: 97/02550 (1997-02-01), None
patent: 97/05250 (1997-02-01), None
patent: 97/09427 (1997-03-01), None
patent: 97/17442 (1997-05-01), None
patent: WO-97/19694 (1997-06-01), None
patent: 98/06844 (1998-02-01), None
patent: 98/07832 (1998-02-01), None
patent: 98/24811 (1998-06-01), None
patent: 98/33917 (1998-06-01), None
patent: 98/39035 (1998-09-01), None
patent: 98/49300 (1998-11-01), None
patent: WO-98/55619 (1998-12-01), None
patent: 98/56936 (1998-12-01), None
patent: 9856936 (1998-12-01), None
patent: WO-99/02545 (1999-01-01), None
patent: 99/08522 (1999-02-01), None
patent: WO-99/20749 (1999-04-01), None
patent: 99/21590 (1999-05-01), None
patent: 99/46364 (1999-09-01), None
patent: WO 99/49882 (1999-10-01), None
patent: WO 00/21560 (2000-04-01), None
patent: WO 00/24412 (2000-05-01), None
patent: WO 00/45835 (2000-08-01), None
patent: WO 00/58511 (2000-10-01), None
patent: WO 00/61186 (2000-10-01), None
patent: WO 00/62798 (2000-10-01), None
patent: WO-00/73430 (2000-12-01), None
patent: WO 00/75163 (2000-12-01), None
patent: WO 00/75163 (2000-12-01), None
patent: WO-01/57226 (2001-08-01), None
patent: WO-01/58956 (2001-08-01), None
patent: WO 02/11769 (2002-02-01), None
patent: WO 02/083704 (2002-10-01), None
patent: WO 02/083849 (2002-10-01), None
patent: WO 02/083850 (2002-10-01), None
patent: WO 03/097660 (2003-11-01), None
patent: WO-97/08320 (2004-03-01), None
patent: 94/3464 (1996-01-01), None
patent: 9-403464 (1996-01-01), None
Litwin et al., “Role of Cytokines in Endothelial Cell Functions,” Human Growth factors: Their role in Disease and Therapy, BB Aggarwal & RK Puri (Eds), Blackwell Science, Inc. USA Chapter 7 101-129 (1995).
Achen et al., “ Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases (VEGF receptor-2 (Flkl) and VEGF receptor 3 (Flt4),” Proc. Natl. Acad. Sci. (USA), 95(2): 548-553 (1998).
Andersson et al., “Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF,” J. Biol. Chem., 267(16): 11260-11266 (1992).
Andersson W.F., “Human gene therapy,”Science, 256:808-813 (1992).
Aprelikova et al., “FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter,” Cancer Research, 52:746-748 (1992).
Dignam et al., “Balbiani ring 3 in chironomus tentans encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar,”Gene88:133-140 (1990).
Ferrara et al., “Molecular and biological properties of the vascular endothelial growth factor family of proteins,”Endocrine Rev. 13(1): 18-32 (1992).
Finnerty et al., “Molecular cloning of murine FLT and FLT4,”Oncogene8(11): 2293-2298 (1993).
Heldin et al., “Structure of platelet-derived growth factor: implications for functional properties,”Growth Factors8:245-252 (1993).
Eichmann et al., “Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGF-2-expressing endothelial cell precursors,”Development125(4): 743-752 (1998).
Pajusola et al., “FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines,”Cancer Research52:5738-5743 (1992).
Leung et al., “Vascular endothelial growth factor is a secreted angiogenic mitogen,”Science246:1306-1309 (1989).
Breier et al., “Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation,”Development114:521-532 (1992).
Bell et al., “Human epidermal growth factor precuror: cDNA sequence, expression in vitro and gene organization,”Nucl. Acids Res. 14(21): 8427-8446 (1986).
Berse et al., Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors,Mol. Biol. Cell. 3:211-220 (1992).
Betsholtz et al., “cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines,”Nature320:695-699 (1986).
Claffey et al., “Vascular endothelial growth factor,”J. Biol. Chem. 267(23): 16317-16322 (1992).
Corson et al., “Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5′ end,”Genomics17:476-484 (1993).
Ferrara et al., “The vascular endothelial growth factor family of polypeptides,”J. Cellular Biochemistry47:211-218 (1991).
George et al., “Current Methods in Sequence Comparison and Analysis,” Macromolecular Seq. and Syn. Selected Meth—Application (Alan R. Liss), pp. 127-149 (1988).
Hu et al., “A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial smooth muscle cells,”FASEB J., 11:498-504 (1997).
Joukov et al., “A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases,”EMBO J. 15(2): 290-298 (1996).
Joukov et al., “Proteolytic processing regulates receptor specific

Affiliated with

Also associated with

Rating

Use of vascular endothelial growth factor to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of vascular endothelial growth factor to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of vascular endothelial growth factor to treat... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3788792